These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36257294)

  • 1. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
    Kim H; Kim JY; Park KU
    Oncology; 2023; 101(1):41-48. PubMed ID: 36257294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.
    Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
    JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.
    Kim H; Kim ST; Yoo KH; Hong JY; Park YS; Lim HY; Park JO
    In Vivo; 2021; 35(1):499-505. PubMed ID: 33402502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
    Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
    Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
    Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
    Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
    Lee S; Shroff RT; Makawita S; Xiao L; Danner De Armas A; Bhosale P; Reddy K; Shalaby A; Raghav K; Pant S; Wolff RA; Javle M
    Clin Cancer Res; 2022 Jun; 28(11):2229-2236. PubMed ID: 35312753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 12. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
    Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
    Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
    Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers.
    Elshami M; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM
    J Surg Res; 2024 Mar; 295():705-716. PubMed ID: 38141457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
    Cosgrove DP; Reese ES; Fulcher NM; Bobiak SS; Lamy FX; Allignol A; Boyd M; Mahmoudpour SH
    Cancer Med; 2023 Feb; 12(4):4195-4205. PubMed ID: 36263922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
    Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.